

Xofigo Market Research and NRC's Training and Experience Requirements for AUs

Ashley Cockerham

Founder & Principal Consultant

Organization of Agreement States Annual Meeting

August 20, 2019



Disclosures

Consultant for:

Bayer HealthCare Pharmaceuticals

Sirtex Medical

NRC Question

Is there a challenge with the current T&E requirements— such as concerns regarding patient access to radiopharmaceuticals— that should be addressed through rulemaking?


YES

Reasons Why

- Geographic distribution limitations of Authorized Users
- Logistical and financial burdens for patients due to additional required office visits


Independent Third-party Market Research

Xofigo Adoption Funnel (All Physicians)




Reasons for Not Referring Patients for Xofigo Despite Recommendation


- Patient's health deteriorated
 - Cost to the patient was too high
 - Patient refused
(not due to travel)
 - Insurance challenges
- Limited access to RO/NM for administration
 - Patient unwilling to travel – no nearby facility




Reasons for Not Referring Patients for Xofigo Despite Recommendation



Reasons for Not Referring Patients for Xofigo Despite Referral



Referral Barriers to Xofigo Prescribing and Administration



Medical oncologists and urologists indicate lack of availability of nuc med specialist / facility as a top 3 barrier

Summary

- Environment created in which not all patients prescribed Xofigo actually receive it
- Geographic distribution of current Authorized Users does not support treatments
- Revise T&E to eliminate barriers related to limited patient access to radiation oncology/nuclear medicine
 - Create T&E pathway for medical oncologists/urologists